Company / SG&A per Share
Dianthus Therapeutics, Inc. /DE/ SG&A per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$1.10
FY2025
5-year range
$0.51 / $7.71
FY2021-FY2025
Trend
-10.0%
vs FY2024
Sector context
#115 of 210
Health Care
What the data says
At $1.10, Dianthus Therapeutics, Inc. /DE/'s sg&a per share ranks #96 of 210 in the Health Care sector. SG&A per Share has declined for 3 consecutive years, from $7.71 in FY2022 to $1.10 in FY2025.
Based on SEC 10-K filings.
1.10 in FY2025 with a 5-year CAGR of +11.5%.
Improved from $3.52 to $1.10 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- -47.7%
- 5-Year CAGR
- +11.5%
- 10-Year CAGR
- -
Sector benchmark
#96 of 210 in Health CareTop 45% of 210This company $1.10 Sector average $29.50
▼
-96.3% below sector average
Key checks
Key Insights
- Dianthus Therapeutics, Inc. /DE/'s sg&a per share has declined for 3 consecutive years.
- In FY2025, sg&a per share decreased 10.0% year-over-year.
- Ranks #115 out of 210 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.10 | -10.0% |
| FY2024 | $1.23 | -65.2% |
| FY2023 | $3.52 | -54.3% |
| FY2022 | $7.71 | +1417.7% |
| FY2021 | $0.51 | -20.5% |
| FY2020 | $0.64 | -10.4% |
| FY2019 | $0.71 | -91.0% |
| FY2018 | $7.92 | +87.9% |
| FY2017 | $4.22 | -81.9% |
| FY2016 | $23.33 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026